Simulations Plus, Inc. (SLP) is a publicly traded Healthcare sector company. As of May 21, 2026, SLP trades at $14.39 with a market cap of $278.43M and a P/E ratio of -4.57. SLP moved +2.77% today. Year to date, SLP is -24.64%; over the trailing twelve months it is -54.90%. Its 52-week range spans $11.09 to $37.67. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces SLP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in SLP news today?
Simulations Plus Q2 Revenue Rises 8% to $24.3M, Guides $79M–$82M Fiscal Sales: Simulations Plus posted Q2 revenue of $24.3M, up 8%, with adjusted EBITDA of $8.7M (36% margin) and EPS of $0.35. Software revenue climbed 9% to 60% of sales, services rose 8%, clinical operations fell 54%, and the company held $41.8M cash while guiding fiscal 2026 revenue to $79M–$82M.
Simulations Plus Q2 Revenue Rises 8% to $24.3M, Guides $79M–$82M Fiscal Sales: Simulations Plus posted Q2 revenue of $24.3M, up 8%, with adjusted EBITDA of $8.7M (36% margin) and EPS of $0.35. Software revenue climbed 9% to 60% of sales, services rose 8%, clinical operations fell 54%, and the company held $41.8M cash while guiding fiscal 2026 revenue to $79M–$82M.
Does Rallies summarize SLP news?
Yes. Rallies summarizes SLP news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is SLP research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SLP. It does not provide personalized investment advice.
